101990-45-8

Basic information

• Product Name: Pyridine, 2-bromo-5-(bromomethyl)- (9CI)
• Synonyms: Pyridine, 2-bromo-5-(bromomethyl)- (9CI);2-Bromo-5-(bromomethyl)pyridine;6-Bromo-3-pyridylmethyl bromide;2-Bromo-5-(bromomethyl)pyridine 96%;3-Pyridineacetonitrile, 6-bromo-;2-Bromo-5-(bromomethyl)
• CAS NO: 101990-45-8
• Molecular Formula: C₆H₅Br₂N
• Molecular Weight: 250.9186
• Product Categories: PYRIDINE;OLED materials,pharm chemical,electronic
• Mol File: 101990-45-8.mol
• Article Data: 54

Chemical Properties

• Melting Point: 60-65°C
• Boiling Point: 296.9±25.0 °C(Predicted)
• Appearance: /
• Density: 1.955
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.12±0.10(Predicted)
• CAS DataBase Reference: Pyridine, 2-bromo-5-(bromomethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 2-bromo-5-(bromomethyl)- (9CI)(101990-45-8)
• EPA Substance Registry System: Pyridine, 2-bromo-5-(bromomethyl)- (9CI)(101990-45-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26
• RIDADR: UN 3335
• WGK Germany: 3
• Hazardous Substances Data: 101990-45-8(Hazardous Substances Data)

Usage

General Description

Pyridine, 2-bromo-5-(bromomethyl)- (9CI) is a chemical compound that belongs to the class of pyridine derivatives. It is characterized by the presence of a bromine atom at the 2nd and 5th position of the pyridine ring, as well as a bromomethyl group attached to the 5th carbon of the ring. Pyridine, 2-bromo-5-(bromomethyl)- (9CI) is commonly used in organic synthesis as a precursor for various pharmaceuticals, agrochemicals, and other fine chemicals. It is also used as a building block in the synthesis of complex molecules due to its reactivity and functional groups. However, it should be handled with caution and proper safety measures as it is considered hazardous and potentially harmful to human health and the environment.

Upstream product

• 3510-66-5 2-Bromo-5-methylpyridine 
• 843646-70-8 (6-bromopyridin-3-yl)methyl methanesulfonate 
• 122306-01-8 2-bromo-5-(hydroxymethyl)pyridine 
• 149806-06-4 6-bromonicotinaldehyde 
• 23100-12-1 6-chloronicotinylaldehyde 
• 70258-18-3 2-chloro-5-(chloromethyl)pyridine 
• 128-08-5 N-Bromosuccinimide 
• 1603-41-4 (5-methyl-pyridin-2-yl)amine 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 58757-38-3 6-Chloronicotinoyl chloride 
• 21543-49-7 2-Chloro-5-hydroxymethylpyridine 
• 7789-60-8 phosphorus tribromide 

Downstream Products

• 144873-99-4 (6-bromopyridine-3-yl)acetonitrile 
• 845973-17-3 C₁₃H₁₂BrN 
• 791789-97-4 (6-bromo-pyridin-3-ylmethyl)-phenethylamine 
• 845973-23-1 C₁₂H₁₀BrNO 
• 462123-60-0 tert-butyl (S)-3-(6-bromopyridin-3-yl)-2-(diphenylmethyleneamino)propanoate 
• 1257426-18-8 (6S)-6-{[6-(4-fluorophenyl)-3-pyridinyl]methoxy}-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1257426-25-7 (6S)-6-({6-[3-fluoro-4-(trifluoromethoxy)phenyl]-3-pyridinyl}methoxy)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1416733-34-0 C₁₇H₁₄F₂N₂O₃ 
• 1416733-35-1 C₂₁H₁₂F₄N₂O₂ 
• 1416733-36-2 C₂₂H₁₄F₄N₂O₂ 
• 1416733-32-8 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(2H-tetrazol-2-yl)propyl)pyridin-3-yl)methoxy)benzonitrile 
• 1416733-31-7 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)methoxy)benzonitrile 
• 1416733-33-9 C₁₃H₉BrN₂O 
• 1448338-04-2 N²-(4-aminocyclohexyl)-N⁶-(6-bromo-pyridin-3-ylmethyl)-9-cyclopentyl-9H-purine-2,6-diamine 

Relevant articles and documents

Design, synthesis and biological evaluation of low molecular weight CXCR4 ligands

The chemokine receptor CXCR4/stromal cell-derived factor-1 (SDF-1: CXCL12) signaling axis represents a crucial drug target due to its relevance to several diseases such as HIV-1 infection, cancer, leukemia, and rheumatoid arthritis. With the aim of enhancing the binding affinity and anti-HIV activity of a potent CXCR4 ligand as a lead, 23 low molecular weight compounds containing dipicolylamine (Dpa) and cyclam cationic moieties with varying spacers and spatial positioning were designed, synthesized and biologically evaluated. All of the synthesized compounds screened at 1.0 μM in the NanoBRET assay system exhibited >70% inhibition of the binding of a competitive probe TAMRA-Ac-TZ14011 (10 nM) to CXCR4 in the presence of zinc (II) ion. Furthermore, selected compounds 3, 8, 9, 19 and 21 with spatial distances between the next carbon to Dpa and the next carbon to cyclam within the range of 6.5–7.5 ? showed potent binding affinity selective for CXCR4 with IC50 values of 1.6, 7.9, 5.7, 3.5 and 4.5 nM, respectively, with corresponding high anti-HIV activity with EC50s of 28, 13, 21, 28 and 61 nM, respectively, in the presence of zinc (II) ion. Some compounds with remarkably more potent CXCR4-binding affinity than that of an initial lead were obtained. These compounds interact with different but overlapping amino acid residues of CXCR4. The present studies have developed new low molecular weight CXCR4 ligands with high CXCR4-binding and anti-HIV activities, which open avenue into the development of more potent CXCR4 ligands.

A comparison of the binding of three series of nicotinic ligands

A total of 24 aryl-substituted analogues of nicotine (1a) and two related series of nicotinic ligands, aminomethylpyridines 3 and ether analogues 8, were examined to determine if they bind at α4β2 nACh receptors in a common manner. A modest correlation (r=0.785) was found between the affinities of the nicotine analogues and derivatives of 3, but little correlation (r=0.348) was found with analogues 8. However, a modest correlation (r=0.742) exists between the binding of analogues 3 and 8. It seems that 1-series and 8-series compounds bind differently but that the 3-series compounds share some intermediate binding similarity with both.

COMPOUND WITH KINASE INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF

Disclosed is a compound as shown in general formulas (I) or (II) and a pharmaceutically acceptable salt, an isomer or a mixture form thereof, a solvate, a polymorph, a stable isotope derivative, or a prodrug of the same. The compound of the present invention has CDK kinase inhibitory activity and can be used in treating a disease related to CDK kinase, such as a cancer.

Preparation method of 2-bromine-5-formylpyridine

The invention relates to the field of fine chemical industry and particularly relates to a preparation method of 2-bromine-5-formylpyridine. The preparation method comprises the following steps: (1) performing an oxidation reaction; (2) performing a bromination reaction. In the preparation method provided by the invention, 2-chlorine-5-chloromethyl pyridine is taken as a raw material, and the 2-bromine-5-formylpyridine is prepared by two steps of reactions: the oxidation reaction and the bromination reaction, so that the method is simple in technological operation, mild and safe in reaction conditions, low in cost of the raw material, high in reaction conversion rate, high in yield and easy in extraction of a product, therefore, the method is more suitable for safe industrial production and has greater implementation value and social and economic benefits.